FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)
Search
Pharmacy Rotations
Click here to read testimonies from our employees who enrolled in our pharmacy rotations academic program.
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Let’s find CKD
More than 35 million Americas are living with chronic kidney disease (CKD), and most of them don’t know it. Early diagnosis of CKD needs to be a national priority.
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Quantum Computing: Boehringer Ingelheim and Google Partner for Pharma R&D
Overcoming stigma and advancing lung cancer advocacy
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
New effort to help improve C-R-M health outcomes
Boehringer Ingelheim sponsors American Heart Association's Cardiovascular Kidney Metabolic Health Intiative (CKMH)
An Employee’s Commitment to Ensuring Access to Medicines
An Employee’s Commitment to Ensuring Access to Medicines
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Our forward-looking approach drives breakthroughs
Our purpose is the patient—so our actions are those of a partner, our vision is always long-term, and our results are measured in lives changed and lives saved.
Lung Diseases
Our Therapeutic Areas
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
Federal and State Laws
Federal and State Laws
Exploring beyond boundaries for innovation in animal health
Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.
Boehringer’s unique approach to innovation
Boehringer’s unique approach to driving patient-centric innovation
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
BI Cares Financial Contributions Program
BI Cares Financial Contributions Program
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Queen Latifah and Bernie Williams star in Boehringer Ingelheim’s “Beyond Breathless” documentary on A&E
Queen Latifah and Bernie Williams star
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Six creative Connecticut students turn aspiring ideas into inventive innovation
Learn about the 2023 Connecticut Invention Convention winners.
Helping pets in hurricane-ravaged Puerto Rico
Helping pets in hurricane-ravaged Puerto Rico